Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
Aged
Aged, 80 and over
Aspirin
/ adverse effects
Chemoprevention
Comorbidity
Dipyridamole
/ adverse effects
Disease Susceptibility
Dose-Response Relationship, Drug
Female
Humans
Leukemia, Lymphoid
/ epidemiology
Lymphoma
/ epidemiology
Male
Middle Aged
Platelet Aggregation Inhibitors
/ adverse effects
Population Surveillance
Propensity Score
Proportional Hazards Models
Registries
Risk Assessment
Risk Factors
Sweden
/ epidemiology
cohort study
dipyridamole
drug repurposing
lymphoid neoplasms
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
10
09
2021
received:
22
08
2021
accepted:
12
09
2021
pubmed:
24
9
2021
medline:
15
2
2022
entrez:
23
9
2021
Statut:
ppublish
Résumé
The anti-cancer potential of dipyridamole has been suggested from experiments, but evidence from population-based studies is still lacking. We aimed to explore if dipyridamole use was related to a lower risk of lymphoid neoplasms. We identified individuals with prescription of aspirin after diagnosis of ischaemic cerebrovascular disease since 2006 by linking several Swedish registers. In these aspirin users, those with dipyridamole prescription were further identified as the study group and patients without dipyridamole were randomly selected as reference group with 1:1 ratio using a propensity score-matching approach. After a median of 6·67 years of follow-up, a total of 46 patients with dipyridamole use developed lymphoid neoplasms with an incidence rate of 0·49 per 1 000 person-years, while the rate in the matched group was 0·74 per 1 000 person-years. As compared to non-users, dipyridamole users were associated with a significantly decreased risk of lymphoid neoplasms [hazard ratio (HR) = 0·65; 95% confidence interval (CI) = 0·43-0·98]. Specifically, the reduced risk was observed for non-Hodgkin lymphomas (HR = 0·64; 95% CI = 0·42-0·94), especially B-cell lymphomas (HR = 0·56; 95% CI = 0·35-0·88). Dipyridamole use was related to a lower risk of lymphoid neoplasms, indicating a clinical potential of dipyridamole to be an adjunct anti-tumour agent against lymphoid neoplasms.
Substances chimiques
Platelet Aggregation Inhibitors
0
Dipyridamole
64ALC7F90C
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
690-699Informations de copyright
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D82.
Balakumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varatharajan R, et al. Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res. 2014;87:144-50.
Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul Pharmacol. 2008;48(4-6):143-9.
Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, Marathe GK, et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111(5):633-42.
Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931-47.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27-41.
Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131(16):1777-89.
Zhou S, Xu H, Tang Q, Xia H, Bi F. Dipyridamole enhances the cytotoxicities of the trametinib against colon cancer cells through combined targeting HMGCS1 and MEK pathway. Mol Cancer Ther. 2019;19:135-46.
Thome MP, Pereira LC, Onzi GR, Rohden F, Ilha M, Guma FT, et al. Dipyridamole impairs autophagic flux and exerts antiproliferative activity on prostate cancer cells. Exp Cell Res. 2019;382(1):111456.
Thome MP, Borde C, Larsen AK, Henriques JAP, Lenz G, Escargueil AE, et al. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation. Antiviral Res. 2019;172:104615.
Choudhary S, Sood S, Wang HC. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog. 2014;53(3):243-52.
Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, et al. Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis. 2013;30(1):47-68.
Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK. Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer. Cancer Prev Res (Phila). 2013;6(5):437-47.
Huang B, Chen Z, Geng L, Wang J, Liang H, Cao Y, et al. Mucosal profiling of pediatric-onset colitis and IBD reveals common pathogenics and therapeutic pathways. Cell. 2019;179(5):1160-76.e24.
Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, Penn LZ. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Mol Oncol. 2020;14(10):2533-45.
Goda AE, Erikson RL, Sakai T, Ahn JS, Kim BY. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol. 2015;9(1):309-22.
Thorley-Lawson DA, Gross A. Persistence of the epstein-barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328-37.
Farrell PJ. Epstein-Barr Virus and Cancer. Annu Rev Pathol. 2019;14:29-53.
Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother. 2000;34(11):1283-90.
Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665-73.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13.
Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360(21):2191-201.
De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. 2007;3:CD001820.
Ji J, Sundquist J, Sundquist K. Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study. Int J Cancer. 2019;144(8):1888-95.
Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382(11):1018-28.
Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the pathology working group of the International lymphoma epidemiology consortium (InterLymph). Blood. 2007;110(2):695-708.
Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson comorbidity index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188-97.
Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbaek H, et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet. 2014;383(9934):2047-56.
Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363-71.
VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268-74.
Baillie GS, Tejeda GS, Kelly MP. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019;18(10):770-96.
Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, et al. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs. 2010;19(1):117-31.
Peng T, Gong J, Jin Y, Zhou Y, Tong R, Wei X, et al. Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem. 2018;150:742-56.
Rickles RJ, Pierce LT, Giordano TP 3rd, Tam WF, McMillin DW, Delmore J, et al. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood. 2010;116(4):593-602.
Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin Cancer Res. 2002;8(2):589-95.
Ekholm D, Mulloy JC, Gao G, Degerman E, Franchini G, Manganiello VC. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes. Biochem Pharmacol. 1999;58(6):935-50.
Bertrand KA, Birmann BM, Chang ET, Spiegelman D, Aster JC, Zhang SM, et al. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma. Blood. 2010;116(18):3547-53.
Teras LR, Rollison DE, Pawlita M, Michel A, Brozy J, de Sanjose S, et al. Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies. Int J Cancer. 2015;136(1):108-16.
Rollison DE, Engels EA, Halsey NA, Shah KV, Viscidi RP, Helzlsouer KJ. Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15(3):543-50.
De Roos AJ, Martínez-Maza O, Jerome KR, Mirick DK, Kopecky KJ, Madeleine MM, et al. Investigation of epstein-barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1747-55.
Coghill AE, Hildesheim A. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol. 2014;180(7):687-95.
Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol. 2012;35(11):673-81.
Piazza GA, Ward A, Chen X, Maxuitenko Y, Coley A, Aboelella NS, et al. PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/beta-catenin transcription, cancer cell growth, and tumor immunity. Drug Discov Today. 2020;25:1521-7.